Our responsibility to people begins in our laboratories but it doesn’t end there. At all stages of the development and use of our medicines, Lilly strives to maintain the highest standards of ethical behaviour.
Lilly is one of the first pharmaceutical companies to have established a standing bioethics committee and later a dedicated bioethics program. The program is designed to address the increasingly complex and fast-paced ethical challenges of global pharmaceutical research, development and commercialisation to protect and advocate for:
the rights and well-being of research participants and patients, and
the integrity of the scientific process and its applications for health care.
The Lilly Bioethics Program
provides bioethics training and education;
consults with teams, functions and business areas on bioethics topics;
develops corporate positions on recurring or impactful bioethics topics;
provides input to policy decisions that have bioethical implications; and
collaborates externally to establish best practices in applying bioethics across the industry.
A key feature of the program is the Bioethics Advisory Committee, which includes internal researchers and business leaders as well as external experts. Visit Lilly’s bioethics page on Lilly.com to learn more.